{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:28:18Z","timestamp":1792783698576,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006676","name":"Lilly Deutschland GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006676","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100031688","name":"Pfizer Pharma GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031688","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006484","name":"AbbVie Deutschland GmbH & Co KG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006484","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol-Myers Squibb GmbH & Co. KGaA"},{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032301","name":"Samsung Bioepis Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032301","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100024149","name":"UCB Pharma GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100024149","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Biocon Biologics Germany GmbH"},{"DOI":"10.13039\/100031723","name":"Amgen GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031723","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Alfasigma S.p.A."},{"DOI":"10.13039\/501100014756","name":"Hexal AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014756","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fresenius Kabi SwissBioSim GmbH"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ard.2025.05.014","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T23:39:53Z","timestamp":1750894793000},"page":"1779-1790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6487-3634","authenticated-orcid":false,"given":"Martin","family":"Schaefer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3458-6764","authenticated-orcid":false,"given":"Alina","family":"Purschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Zietemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7467-7901","authenticated-orcid":false,"given":"Tatjana","family":"Rudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0147-4112","authenticated-orcid":false,"given":"Yvette","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3372-2021","authenticated-orcid":false,"given":"Adrian","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0919-5137","authenticated-orcid":false,"given":"Sylvia","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Rockwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2106-9196","authenticated-orcid":false,"given":"Karl Matthias","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2456-4049","authenticated-orcid":false,"given":"Anne C.","family":"Regierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-022X","authenticated-orcid":false,"given":"Anja","family":"Strangfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ard.2025.05.014_bib0001","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.berh.2019.03.011","article-title":"Malignancy and rheumatoid arthritis: epidemiology, risk factors and management","volume":"32","author":"De Cock","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.ard.2025.05.014_bib0002","first-page":"993","article-title":"Chronic diseases, medical history and familial cancer, and risk of leukemia and non-Hodgkin\u2019s lymphoma in an adult population: a case-control study","volume":"26","author":"Parodi","year":"2015","journal-title":"Cancer Causes Control"},{"issue":"1","key":"10.1016\/j.ard.2025.05.014_bib0003","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2025.05.014_bib0004","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4609486","article-title":"Risk of malignant neoplasm in patients with incident rheumatoid arthritis 1980-2007 in relation to a comparator cohort: a population-based study","volume":"2016","author":"Raheel","year":"2016","journal-title":"Int J Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.05.014_bib0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13075-017-1482-y","article-title":"The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs","volume":"19","author":"Cho","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.ard.2025.05.014_bib0006","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden","volume":"177","author":"Wadstr\u00f6m","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"Pt 8","key":"10.1016\/j.ard.2025.05.014_bib0007","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J Cell Sci"},{"issue":"7","key":"10.1016\/j.ard.2025.05.014_bib0008","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"issue":"21","key":"10.1016\/j.ard.2025.05.014_bib0009","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ard.2025.05.014_bib0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O\u2019Shea","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ard.2025.05.014_bib0011","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.ard.2025.05.014_bib0012","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.05.014_bib0013","series-title":"Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib) [Internet]","year":"2021"},{"key":"10.1016\/j.ard.2025.05.014_bib0014","series-title":"Xeljanz (tofacitinib): initial clinical trial results of increased risk of major adverse cardiovascular events and malignancies (excluding NMSC) with use of tofacitinib relative to TNF-alpha inhibitors [Internet]","year":"2021"},{"issue":"1","key":"10.1016\/j.ard.2025.05.014_bib0015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40744-022-00505-1","article-title":"Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases","volume":"10","author":"Salinas","year":"2023","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.ard.2025.05.014_bib0016","series-title":"EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders (EMA\/27681\/2023) [Internet]","year":"2023"},{"issue":"1","key":"10.1016\/j.ard.2025.05.014_bib0017","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2025.05.014_bib0018","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/ard-2022-223636","article-title":"Behalf of the ARTIS group, et al. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study","volume":"82","author":"Huss","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ard.2025.05.014_bib0019","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/art.42250","article-title":"Tofacitinib and risk of malignancy: results from the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) study","volume":"74","author":"Khosrow-Khavar","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.05.014_bib0020","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2023045","article-title":"Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data","volume":"45","author":"Min","year":"2023","journal-title":"Epidemiol Health"},{"issue":"2","key":"10.1016\/j.ard.2025.05.014_bib0021","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/rheumatology\/kead198","article-title":"Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry","volume":"63","author":"Mok","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ard.2025.05.014_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002614","article-title":"Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study","volume":"8","author":"Song","year":"2022","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2025.05.014_bib0023","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/rheumatology\/kead163","article-title":"Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study","volume":"63","author":"Westermann","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.ard.2025.05.014_bib0024","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"5 Suppl 101","key":"10.1016\/j.ard.2025.05.014_bib0025","first-page":"S79","article-title":"Primary and secondary patient data in contrast: the use of observational studies like RABBIT","volume":"34","author":"Richter","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.05.014_bib0026","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.annepidem.2023.05.004","article-title":"The application of lag times in cancer pharmacoepidemiology: a narrative review","volume":"84","author":"Hicks","year":"2023","journal-title":"Ann Epidemiol"},{"issue":"2","key":"10.1016\/j.ard.2025.05.014_bib0027","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/oxfordjournals.aje.a115507","article-title":"A simple method to calculate the confidence interval of a standardized mortality ratio (SMR)","volume":"131","author":"Ulm","year":"1990","journal-title":"Am J Epidemiol"},{"issue":"446","key":"10.1016\/j.ard.2025.05.014_bib0028","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"408","key":"10.1016\/j.ard.2025.05.014_bib0029","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The robust inference for the Cox proportional hazards model","volume":"84","author":"Lin","year":"1989","journal-title":"J Am Stat Assoc"},{"issue":"27","key":"10.1016\/j.ard.2025.05.014_bib0030","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"issue":"7","key":"10.1016\/j.ard.2025.05.014_bib0031","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.ard.2025.05.014_bib0032","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","article-title":"IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer","volume":"15","author":"Grivennikov","year":"2009","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ard.2025.05.014_bib0033","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.ard.2025.05.014_bib0034","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1185\/03007995.2015.1011778","article-title":"Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk","volume":"31","author":"Lebrec","year":"2015","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.ard.2025.05.014_bib0035","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.ard.2025.05.014_bib0036","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0962280206074463","article-title":"Multiple imputation of discrete and continuous data by fully conditional specification","volume":"16","author":"van Buuren","year":"2007","journal-title":"Stat Methods Med Res"},{"issue":"3","key":"10.1016\/j.ard.2025.05.014_bib0037","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/sim.3783","article-title":"Estimation of intervention effects using first or multiple episodes in clinical trials: the Andersen-Gill model re-examined","volume":"29","author":"Cheung","year":"2010","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.ard.2025.05.014_bib0038","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3414\/ME0478","article-title":"Modeling repeated time-to-event health conditions with discontinuous risk intervals. An example of a longitudinal study of functional disability among older persons","volume":"47","author":"Guo","year":"2008","journal-title":"Methods Inf Med"},{"issue":"1","key":"10.1016\/j.ard.2025.05.014_bib0039","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/1475-2875-13-293","article-title":"Modelling recurrent events: comparison of statistical models with continuous and discontinuous risk intervals on recurrent malaria episodes data","volume":"13","author":"Sagara","year":"2014","journal-title":"Malar J"},{"issue":"4","key":"10.1016\/j.ard.2025.05.014_bib0040","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox\u2019s regression model for counting processes: a large sample study","volume":"10","author":"Andersen","year":"1982","journal-title":"Ann Stat"},{"issue":"10","key":"10.1016\/j.ard.2025.05.014_bib0041","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/sim.9681","article-title":"A comparison of different methods to adjust survival curves for confounders","volume":"42","author":"Denz","year":"2023","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.ard.2025.05.014_bib0042","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2025.05.014_bib0043","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/s41416-023-02544-z","article-title":"Minimum latency effects for cancer associated with exposures to radiation or other carcinogens","volume":"130","author":"Little","year":"2024","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ard.2025.05.014_bib0044","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/bcpt.12946","article-title":"Considerations for pharmacoepidemiological studies of drug-cancer associations","volume":"122","author":"Potteg\u00e5rd","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.ard.2025.05.014_bib0045","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/pds.4145","article-title":"New use of prescription drugs prior to a cancer diagnosis","volume":"26","author":"Potteg\u00e5rd","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1016\/j.ard.2025.05.014_bib0046","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.05.014_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001565","article-title":"RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?","volume":"7","author":"Strand","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.05.014_bib0048","series-title":"Modeling survival data: extending the Cox model","first-page":"350 p","author":"Therneau","year":"2000"},{"issue":"11","key":"10.1016\/j.ard.2025.05.014_bib0049","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s43587-024-00692-2","article-title":"Nonlinear dynamics of multi-omics profiles during human aging","volume":"4","author":"Shen","year":"2024","journal-title":"Nat Aging"},{"issue":"1","key":"10.1016\/j.ard.2025.05.014_bib0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/pds.5547","article-title":"Core concepts in pharmacoepidemiology: key biases arising in pharmacoepidemiologic studies","volume":"32","author":"Acton","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725010246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725010246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T04:16:30Z","timestamp":1779855390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725010246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0003496725010246"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.05.014","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}